美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

305.74

+11.233.81%

盘后：305.740.00000.00%16:10 EDT

成交量：78.92万

成交额：2.41亿

市值：362.76亿

市盈率：-82.56

高：308.87

开：304.33

低：299.44

收：294.51

数据加载中...

总览公司新闻公告

百济神州的新时代

百济神州6月27日成交额为9694.06万美元

百济神州研发日：未来 18 个月，预计将迎来 20 项里程碑进展

Insight数据库

百济神州的医保猜想：领先外企一个身位，还有必要谈吗？

叮当健康旗下药房上架百济神州注射用泽尼达妥单抗(百赫安)

国产创新药破晓时刻！华安医药军团以科技思维定义投资新范式

港股生物医药股延续回调，百济神州跌超8%

老虎资讯综合

6 月，恒瑞、百济神州、复星医药等新药又有新进展，多个关键 III 期临床启动

Insight数据库

解读全球制药企业50强榜单：中国创新药企距离“Big Pharma”还有多远

每日经济新闻

百济神州在研发日展示开创性肿瘤治疗管线

医药估值重估逻辑

资本市场那些事儿

百济神州百悦泽®片剂获欧洲药品管理局人用药品委员会积极意见

百济神州6月24日成交额为1.20亿美元

"长守护悦新生"2025淋巴瘤患者关爱活动举行

创新药大牛市继续，最受益也是中国最强的创新药龙头，没有之一！

价值事务所

港股创新药ETF涨2.25%，成交额23.73亿元

百济神州：生物科技出海明星 2025年迎来蝶变

西南证券股份有...

百济神州6月23日成交额为1.16亿美元

【医药生物】创新药审评再次加速，创新药产业链主线持续明确——医药生物行业跨市场周报（20250622）（王明瑞）

光大证券研究

百济神州涨逾3% 百赫安于中国正式投入临床使用

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ONC/news?page=6"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":305.74,"timestamp":1753819200000,"preClose":294.51,"halted":0,"volume":789183,"hourTrading":{"tag":"盘后","latestPrice":305.74,"preClose":305.74,"latestTime":"16:10 EDT","volume":6502,"amount":1988059.51746,"timestamp":1753819803989},"delay":0,"floatShares":75541600,"shares":118650120,"eps":-3.70325,"marketStatus":"盘后交易","change":11.23,"latestTime":"07-29 16:44:32 EDT","open":304.325,"high":308.87,"low":299.44,"amount":240607843.618239,"amplitude":0.032019,"askPrice":309.7,"askSize":320,"bidPrice":305,"bidSize":164,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1753833600000},"marketStatusCode":4,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":294.51,"preHourTrading":{"tag":"盘前","latestPrice":305.5,"preClose":294.51,"latestTime":"09:29 EDT","volume":9412,"amount":2821290.2952,"timestamp":1753795780069},"postHourTrading":{"tag":"盘后","latestPrice":305.74,"preClose":305.74,"latestTime":"16:10 EDT","volume":6502,"amount":1988059.51746,"timestamp":1753819803989},"volumeRatio":2.669935,"impliedVol":0.4505,"impliedVolPercentile":0.7042},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":2.669935,"shares":118650120,"dividePrice":0,"high":308.87,"amplitude":0.032019,"preClose":294.51,"low":299.44,"week52Low":155.75,"pbRate":"10.37","psRate":"8.69","week52High":308.87,"institutionHeld":0,"latestPrice":305.74,"committee":-0.322314,"eps":-3.70325,"divideRate":0,"volume":789183,"delay":0,"ttmEps":-3.70325,"open":304.325,"prevYearClose":184.71,"prevWeekClose":291.47,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":295.59,"twentyDayClose":242.07,"sixtyDayClose":255.64,"earningDate":1754409600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2547085826","title":"百济神州的新时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2547085826","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547085826?lang=zh_cn&edition=fundamental","pubTime":"2025-06-29 16:37","pubTimestamp":1751186273,"startTime":"0","endTime":"0","summary":"继首季度盈利之后，近日举办的投资者研发日活动让百济神州又一次站在聚光灯下。泽布替尼只是开始，百济神州血液瘤的上市产品格局即将焕新，新王牌索托克拉已在华申报上市，并预计在今年下半年推进全球申报。基于此，百济神州将在今年Q3开放乳腺癌和妇科恶性肿瘤的肿瘤特异性扩展队列，以进一步确认BG-C9074在B7-H4高表达肿瘤患者中的疗效和安全性。在肺癌领域，百济神州正在打造行业领先的产品组合。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629164711a723c846&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629164711a723c846&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","LU2328871848.SGD","ONC","LU0588546209.SGD","BK1500","LU0307460666.USD","06160","BK1583","LU1969619763.USD","BK1161","BK1588"],"gpt_icon":0},{"id":"2546763867","title":"百济神州6月27日成交额为9694.06万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546763867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546763867?lang=zh_cn&edition=fundamental","pubTime":"2025-06-28 12:18","pubTimestamp":1751084322,"startTime":"0","endTime":"0","summary":"美东时间2025年6月27日，百济神州成交额为9694.06万美元，成交额较昨日减少9.17%，当日成交量为40.08万股。百济神州于2025年6月27日跌5.22%，报241.2美元，该股过去5个交易日跌2.38%，年初至今涨30.58%，过去60日跌11.01%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628121843a7220f4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628121843a7220f4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2546772031","title":"百济神州研发日：未来 18 个月，预计将迎来 20 项里程碑进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2546772031","media":"Insight数据库","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546772031?lang=zh_cn&edition=fundamental","pubTime":"2025-06-28 08:04","pubTimestamp":1751069069,"startTime":"0","endTime":"0","summary":"6 月 26 日，百济神州举行了投资者研发日活动。未来 18 个月内，预计将迎来 20 项里程碑进展。百济神州现拥有 1200+名科研人员，覆盖多样化的治疗模式。截至 5 月 28 日，百济正在进行临床开发的产品有 30 个，进行中的临床试验有 96 项。百济神州是唯一一家在 3 个 CLL 基础作用机制中均拥有潜在 BIC 产品的公司。预期里程碑事件展望未来 18 个月，百济神州将有望迎来多个关键后期催化剂和关键早期催化剂事件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628081518a721bdba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628081518a721bdba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","688235","BK0239"],"gpt_icon":0},{"id":"2546774624","title":"百济神州的医保猜想：领先外企一个身位，还有必要谈吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2546774624","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546774624?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 20:46","pubTimestamp":1751028396,"startTime":"0","endTime":"0","summary":"5月29日，百济神州HER2靶点的重磅新药泽尼达妥单抗正式获批上市，用于治疗既往接受过全身治疗的HER2高表达不可切除局部晚期或转移性胆道癌患者。泽尼达妥单抗成为全球首个且目前唯一获批用于靶向治疗HER2高表达胆道癌的产品，领先一个身位。据百济神州官方最新消息，首批泽尼达妥单抗已经在全国百余个城市的医院和药房落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627210128a4c14cea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627210128a4c14cea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","BK4526","688235","BK4139"],"gpt_icon":0},{"id":"2546671877","title":"叮当健康旗下药房上架百济神州注射用泽尼达妥单抗(百赫安)","url":"https://stock-news.laohu8.com/highlight/detail?id=2546671877","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546671877?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 16:48","pubTimestamp":1751014120,"startTime":"0","endTime":"0","summary":"日前, 百济神州双特异性HER2抑制剂百赫安首批药物在叮当健康旗下药房等渠道上架发售,6 月24日,于叮当健康旗下药房正式售出首单。注射用泽尼达妥单抗于2025年5月29日,获附条件批准,用于既往接受过治疗的患者。据了解,叮当健康于2025年持续推进新特药‘生命方舟计划’,在旗下药房全面加强新特药品类布局,已先后上架阿尔茨海默病药品记能达、1类新药注射用瑞康曲妥珠单抗(艾维达)等新特药产品,为提升患者用药可及性带来便利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627165221952ddb11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627165221952ddb11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","09886","688235","06160","ONC"],"gpt_icon":0},{"id":"2546761985","title":"国产创新药破晓时刻！华安医药军团以科技思维定义投资新范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2546761985","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546761985?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 10:20","pubTimestamp":1750990844,"startTime":"0","endTime":"0","summary":"华安医药军团凭借多元化产品矩阵满足不同需求，汇聚产业专家，以科技投资思维构建研究体系。创新药的“破晓时刻”，医药投资的复苏拐点 在国内政策强力扶持、全球竞争力显著提升、出海浪潮集中爆发等多重因素驱动下，2025年，中国创新药行业迎来了属于自己的“破晓时刻”。截至一季度末，华安医药生物持仓包括港股市场和A股市场中多只涨幅明显的创新药个股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627102044a71fcded&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627102044a71fcded&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","09969","BK4526","BK4139","688428","ONC","688235"],"gpt_icon":0},{"id":"1106218367","title":"港股生物医药股延续回调，百济神州跌超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106218367","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106218367?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 10:13","pubTimestamp":1750990427,"startTime":"0","endTime":"0","summary":"6月27日，港股生物医药股延续回调，百济神州跌超8%，荣昌生物跌超7%，北海康成跌超6%，加科思、中国再生医学、药明巨诺跌超4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","688235","06160","LU0307460666.USD","BK4139","BK0239","BK1588","ONC","07226","LU1969619763.USD","BK4614","YANG","399441","HSTECH","161726","BK4526","BK1161","LU0588546209.SGD","HSCEI","LU2328871848.SGD"],"gpt_icon":0},{"id":"2546575067","title":"6 月，恒瑞、百济神州、复星医药等新药又有新进展，多个关键 III 期临床启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2546575067","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546575067?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 07:45","pubTimestamp":1750981540,"startTime":"0","endTime":"0","summary":"III 期临床启动，意味着新药研发已经开始向上市申请发起冲刺。据公开资料，这是该药首次启动 III 期临床。国产方面，三生国健的 SSGJ-611 本次启动 COPD III 期临床。此外，康诺亚/石药集团的司普奇拜单抗已启动 II/III 期，康乃德/先声药业的乐德奇拜单抗正在开展 II 期临床。Insight 数据库显示，在低级别胶质瘤赛道上，国内暂未有相关药物获批上市，芦沃美替尼研发进度位列第一梯队，已开展 III 期关键临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627075121a4bfe6d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627075121a4bfe6d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","BK0187","BK0060","ONC","BK0096","BK0028","BK0196","600276","02196","688235","01276","BK0239","600196","06160","BK0188","BK0012","BK0175"],"gpt_icon":0},{"id":"2546780647","title":"解读全球制药企业50强榜单：中国创新药企距离“Big Pharma”还有多远","url":"https://stock-news.laohu8.com/highlight/detail?id=2546780647","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546780647?lang=zh_cn&edition=fundamental","pubTime":"2025-06-26 20:02","pubTimestamp":1750939355,"startTime":"0","endTime":"0","summary":"近日，美国《制药经理人》杂志发布2025年全球制药企业50强榜单。从产品潜力和研发趋势来看，中国创新药领域的全球化征程已经起航，成为“Big Pharma”只是时间问题。Evaluate Pharma近期发布的最新预测报告表示，到2030年，GLP-1激动剂及相关复方制剂将占所有处方药销售额的近9%。中国药企在前沿疗法“唱主角”上述榜单显示，今年有6家中国企业上榜，数量创近5年新高，但排名均在30名以后。但中国创新药近年来取得的进步有目共睹。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626200338a4bf27b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626200338a4bf27b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","NVO","159992","BK0239","06160","MRK"],"gpt_icon":0},{"id":"2546978975","title":"百济神州在研发日展示开创性肿瘤治疗管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2546978975","media":"百济神州","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546978975?lang=zh_cn&edition=fundamental","pubTime":"2025-06-26 18:07","pubTimestamp":1750932471,"startTime":"0","endTime":"0","summary":"在百济神州，我们的使命明确且坚定——致力于成为推动全球新一代肿瘤治疗创新的先行者。如今，百济神州汇集了超过1200名科学家和3700多名临床开发及医学事务的专业人才，共同致力于推动肿瘤治疗领域的持续突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626182027a4beffdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626182027a4beffdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0329678170.USD","ONC","BK1583","LU2328871848.SGD","LU0588546209.SGD","BK1588","LU0737861772.HKD","LU0329678337.USD","688235","LU0307460666.USD","LU2488822045.USD","BK1161","BK1500","06078","06160","BK1209","LU1969619763.USD"],"gpt_icon":0},{"id":"2546278232","title":"医药估值重估逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2546278232","media":"资本市场那些事儿","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546278232?lang=zh_cn&edition=fundamental","pubTime":"2025-06-26 09:14","pubTimestamp":1750900469,"startTime":"0","endTime":"0","summary":"为什么我会提出这个概念，因为2025，有了一些新变化，对比以往的医药行业，估值的重估，开始一步步的被证实了。——海外大佬来“抢货”大药企“囤货式采购”：2025年起，辉瑞、默沙东等国际巨头疯狂抢购中国创新药管线，尤其是早期项目。叠加大药企的专利陆续到期，都到中国来扫货了。2024年32家药企研发投入672亿，35%砸向早期项目。药企猛冲研发，CXO躺赚订单，技术平台型药企和CXO公司都能迎来一波估值重估。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626092555a4be36c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626092555a4be36c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","01530","06160","BK4139","BK4526","688235","09926"],"gpt_icon":0},{"id":"2546421137","title":"百济神州百悦泽®片剂获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2546421137","media":"百济神州","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546421137?lang=zh_cn&edition=fundamental","pubTime":"2025-06-25 18:06","pubTimestamp":1750845997,"startTime":"0","endTime":"0","summary":"美国加州圣卡洛斯——百济神州有限公司是一家全球肿瘤治疗创新公司，今日宣布欧洲药品管理局人用药品委员会发布积极意见，推荐批准百悦泽新的薄膜包衣片剂剂型用于所有已获批适应症。欧盟委员会将对CHMP的积极意见进行审评，如通过批准，片剂剂型在欧盟和欧洲经济区国家挪威和冰岛上市。本新闻稿中的所有信息仅及于新闻稿发布之日，除非法律要求，百济神州并无责任更新该等信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625183749a4bd317c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625183749a4bd317c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","ONC","06160"],"gpt_icon":0},{"id":"2546726445","title":"百济神州6月24日成交额为1.20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546726445","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546726445?lang=zh_cn&edition=fundamental","pubTime":"2025-06-25 12:34","pubTimestamp":1750826076,"startTime":"0","endTime":"0","summary":"美东时间2025年6月24日，百济神州成交额为1.20亿美元，成交额较昨日增加3.37%，当日成交量为45.06万股。百济神州于2025年6月24日涨3.61%，报266.8美元，该股过去5个交易日涨0.9%，年初至今涨44.44%，过去60日涨1.6%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625123445a71c564b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625123445a71c564b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2546232068","title":"\"长守护 悦新生\"2025淋巴瘤患者关爱活动举行","url":"https://stock-news.laohu8.com/highlight/detail?id=2546232068","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546232068?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 21:45","pubTimestamp":1750772700,"startTime":"0","endTime":"0","summary":"\"长守护 悦新生\"2025淋巴瘤患者关爱活动  淋巴瘤是我国最常见的血液系统肿瘤之一，具有分型复杂、起病隐匿、早期诊断难度大、病程长且易复发等特点，为患者及其家庭带来了较为沉重的疾病负担。淋巴瘤患者故事纪录片《英雄》也在活动现场首映。影片讲述了三位不同年龄、不同职业的淋巴瘤患者积极治疗、热爱生活的真实故事，激励更多患友要做生活中的英雄。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4717198_ZH17198_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06160","BK1500","BK1583","BK1588","BK4139","688235","LU0307460666.USD","LU1969619763.USD","BK0239","BK1161","LU0588546209.SGD","LU2328871848.SGD","BK4526","ONC"],"gpt_icon":0},{"id":"2545805762","title":"创新药大牛市继续，最受益也是中国最强的创新药龙头，没有之一！","url":"https://stock-news.laohu8.com/highlight/detail?id=2545805762","media":"价值事务所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545805762?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 20:58","pubTimestamp":1750769912,"startTime":"0","endTime":"0","summary":"连当代创新药的发源地欧美都开始争相关注并报道咱们国内的创新药突破，这其实就已经很能够说明一些问题了。这不仅是百济自身的转折点，其实也是国内创新药行业从 “资本驱动” 迈向 “价值创造” 的重要信号。对大多数 Biotech 而言，这样的路径既是范本，也是九死一生的缩影。创新药的上岸之路，从来都是烧钱换时间的残酷游戏。如今国内创新药崛起之势不","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624210233a4bb8bd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624210233a4bb8bd9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4614","ONC","688235","BK4526","YANG","06160"],"gpt_icon":0},{"id":"2545523545","title":"港股创新药ETF涨2.25%，成交额23.73亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545523545","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545523545?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 15:04","pubTimestamp":1750748662,"startTime":"0","endTime":"0","summary":"6月24日，港股创新药ETF收盘涨2.25%，成交额23.73亿元。港股创新药ETF成立于2024年1月3日，基金全称为银华国证港股通创新药交易型开放式指数证券投资基金，基金简称为港股创新药ETF。回顾2024年12月31日，港股创新药ETF份额为3.95亿份，规模为3.78亿元。流动性方面，截止6月24日，港股创新药ETF近20个交易日累计成交金额384.34亿元，日均成交金额19.22亿元；今年以来，113个交易日，累计成交金额793.25亿元，日均成交金额7.02亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624222703a4bbaa2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624222703a4bbaa2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4139"],"gpt_icon":0},{"id":"2545474477","title":"百济神州：生物科技出海明星 2025年迎来蝶变","url":"https://stock-news.laohu8.com/highlight/detail?id=2545474477","media":"西南证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545474477?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 13:40","pubTimestamp":1750743628,"startTime":"0","endTime":"0","summary":"2）在研Bcl-2i 和BTK CDAC 于2025 年迎来多项催化事件，未来依托泽布替尼全球商业化渠道，拓宽加深血液瘤市场覆盖。百济神州国内药企出海标杆，预计公司25 年有望盈利。百济神州于2010 年创立，是美股+H 股+A 股三地上市的创新药企业。公司于2025 年JPM 大会宣布当年目标实现营运利润为正。2025 年公司Bcl2i Sonrotoclax 有望完成首个注册临床研究。PanKRASi、EGFR CDAC、CDK2i、多项ADC 有望于2025 年下半年首次读出概念验证数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624134036978c50ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624134036978c50ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","159837","BK0239","ONC"],"gpt_icon":0},{"id":"2545792114","title":"百济神州6月23日成交额为1.16亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545792114","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545792114?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 12:33","pubTimestamp":1750739600,"startTime":"0","endTime":"0","summary":"美东时间2025年6月23日，百济神州成交额为1.16亿美元，成交额较昨日增加103.45%，当日成交量为45.07万股。百济神州于2025年6月23日涨4.22%，报257.51美元，该股过去5个交易日跌4.5%，年初至今涨39.41%，过去60日涨2.63%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624123324a71a8aed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624123324a71a8aed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2545142588","title":"【医药生物】创新药审评再次加速，创新药产业链主线持续明确——医药生物行业跨市场周报（20250622）（王明瑞）","url":"https://stock-news.laohu8.com/highlight/detail?id=2545142588","media":"光大证券研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545142588?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 07:02","pubTimestamp":1750719778,"startTime":"0","endTime":"0","summary":"非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。H股恒生医疗健康指数上周收跌7.72%，跑输恒生国企指数6.24pp。众生药业的RAY1225、恒瑞医药的HRS-1893正在进行三期临床；翰森制药的HS-10370、三生制药的SSGJ-612正在进行一期临床。本周观点：创新药审评再次加速，创新药产业链主线持续明确2025年6月16日，国家药监局综合司公开征求《关于优化创新药临床试验审评审批有关事项的公告》意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624070629a71a09c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624070629a71a09c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","01530","03692","BK1574","06978","BK1583","ONC","600276","06160","BK1161"],"gpt_icon":0},{"id":"2545445611","title":"百济神州涨逾3% 百赫安 于中国正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2545445611","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545445611?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 22:50","pubTimestamp":1750690206,"startTime":"0","endTime":"0","summary":"周一，百济神州(ONC.US)涨逾3%，报255.81美元。消息面上，百济神州6月23日宣布双特异性HER2抑制剂百赫安(注射用泽尼达妥单抗)在中国正式供应，并同步在全国多家医疗机构投入临床使用。作为中国首个且目前唯一1获批用于靶向治疗HER2高表达胆道癌的双特异性抗体，首批药物将迅速在全国百余个城市的医院和药房落地，惠及胆道癌(BTC)患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623233944a4b96864&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623233944a4b96864&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":6,"totalSize":165,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盘前","dateTimestamp":1756526400000,"actualEps":null},{"date":"2025-08-06","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.48,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748491200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-28","current":-88.139519,"percent":0.020619,"low":-89.808695,"twenty":-48.706479,"median":-39.743509,"eighty":-23.201674,"high":-19.234246,"avg":-41.250719,"sd":19.489835,"marketCap":34582950476},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-07-28","current":-88.139519,"twenty":-48.706479,"median":-39.743509,"eighty":-23.201674,"marketCap":34582950476}],"updateTime":1753821872635}}}